FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1852-1853 December 20, 2001 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Agnelli et al. (July 19 issue)¹ report the results of one of the few large trials addressing the optimal duration of anticoagulant therapy after a first episode of idiopathic deep-vein thrombosis. They state that improving risk stratification among patients with deep-vein thrombosis is a major concern.

Markers of the activation of coagulation may be of value. Besides prothrombin fragment F1+2, the thrombin–antithrombin complex, plasminogen-activator inhibitor type 1, and tissue-plasminogen-activator antigen, d-dimer may be a good candidate. It is a specific clot-lysis product with a high negative predictive value for ruling out acute thromboembolic venous disease.² The predictive . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.